Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

China Pharma Starts Clinical Trial for Hypertension Drug

publication date: Feb 16, 2009

China Pharma Holdings, Inc. has begun a clinical trial of a generic version of the hypertension drug Candesartan. China Pharma expects the trial will take 18 months to complete. Originally developed by Takeda Pharma of Japan together with AstraZeneca, Cardesartan is a front-line treatment for hypertension. It produced $2.5 billion in revenues worldwide during 2007. China Pharma is actively adding to its portfolio of generic drugs. More details...

Stock Symbols: (OTCBB: CPHI) (NYSE: AZN)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital